Status:
COMPLETED
Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine
Lead Sponsor:
Hopital Lariboisière
Conditions:
HIV Seropositivity
Eligibility:
MALE
18-55 years
Brief Summary
HIV+ patients are considered at risk for excessive bone fragility. Several factors could contribute: age, male sex, low body mass index (BMI), HIV infection per se, vitamin D deficiency, using tenofov...
Detailed Description
Fluoride metabolism will be studied by measurement of fluoride in blood and in daily urine, bone remodelling by measurement of P1NP. Dual X-ray absorptiometry (DXA) will be used to determine the areal...
Eligibility Criteria
Inclusion
- HIV+ patients
- male patients
- patients treated by tenofovir+emtricitabine(TRUVADA®) or tenofovir(VIREAD®) for more than 60 months.
Exclusion
- chronic use of fluoroquinolones, antifungal agents, steroids
- malignancy (current or previous) requiring chemotherapy or radiotherapy
Key Trial Info
Start Date :
May 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT01813292
Start Date
May 1 2013
End Date
July 1 2014
Last Update
November 22 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Lariboisiere
Paris, France, 75475